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Paragangliomas of the head and neck are a group of neoplasms which occur very rarely. Most of them are benign 
tumours. Tinnitus, headaches and dysfunction of the cranial nerves are typical symptoms. Some paragangliomas 
have metastatic abilities and they can produce catecholamines. There are some typical imaging features in CT and 
MRI scans which help to determine the correct diagnosis without the necessity of performing a biopsy which can be 
associated with a haemorrhage risk. Therapeutic management consists of the choice between an active observation, 
surgical procedure, as well as radiotherapy and systemic therapy in the case of malignant paragangliomas. 
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Introduction 
Paragangliomas comprise a group of rarely occurring, 
richly vascularised, slowly growing, encapsulated neuroen-
docrine tumours, which develop in various locations of the 
body, most frequently between the third and sixth decade 
of life. Taking into consideration the usual benign pathology 
of paragangliomas, it might seem that they do not pose a 
serious problem for oncologists specialising in the treatment 
of malignant tumours of the head and neck region. Such an 
opinion may also result from the published epidemiological 
data which specify the incidence of paragangliomas below 
0.5% of all tumours of the head and neck region, which 
makes up about 0.03% of all cancers [1, 2] as well as from 
the data from the National Cancer Register: in 2000–2015 
only 397 cases of tumours developing from the paraganglial 
tissue in adrenal and extra-adrenal locations were reported 
[3]. On the other hand, however, it must be remembered that 
within the course of the disease, distant metastases might 
occur; the multifocal character of these tumours paired with 
their ability to produce catecholamines can lead to a direct 
threat to patients’ lives.
Etiopathogenesis 
These rare tumours develop from paraganglia, which 
are the accumulations of endocrine cells originating in the 
neural crest [4]. Paraganglia are dispersed along the auto-
nomic nervous system in the vicinity of sympathetic and 
parasympathetic neural ganglia or along cranial nerves 
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and large blood vessels. Sympathetic paraganglia have a 
secretory character and thus secrete catecholamines, whilst 
parasympathetic paraganglia belong to chemoreceptors 
and have a receptive character [5]. The division of paragan-
gliomas is presented in Table I. The largest accumulation of 
paraganglial tissue is located in the adrenal cortex. Tumours 
originating in this location are defined as pheochromocy-
tomas, and, according to published data, they are the most 
frequently occurring tumours of the paraganglial system. In 
the WHO classification, neoplasms developing from extra-
-adrenal paraganglia are defined as paragangliomas [5, 6]. 
Paragangliomas of the head and neck region are very rare, 
making up less than 1% of all paragangliomas. Their most 
frequent location in the head and neck region are the follo-
wing areas: carotid bodies (60% cases), the jugulotympanic 
area and vagal nerve area (most frequently within a distance 
of 2 cm from the skull base) [7].
Nomenclature 
The nomenclature of paragangliomas requires syste-
matisation. The generally operating term, chemodectoma, 
should in fact refer solely to the tumours of the area of the 
carotid and aortic bodies, as paraganglia which originate 
from them, also play the role of chemoreceptors. The most 
misleading term for paraganglioma, which is frequently 
used, is glomus tumour. In histology this term refers to the 
classification of tumours originating from the dermis and 
subdermal tissue, precisely from the blood vessels, most 
frequently with a subungual location. Therefore, the use of 
the term glomus tumour in reference to paraganglioma is 
an essential error. Recommended terminology, according to 
the WHO, is meant to refer to paragangliomas with reference 
to their location, e.g. vagal paraganglioma [7].
In accordance with the classification of head and neck 
tumours presented by the World Health Organisation (WHO) 
in 2017, head and neck paragangliomas can be divided into 
the following: 
 — carotid body paraganglioma
 — laryngeal paraganglioma
 — middle ear paraganglioma
 — vagal paraganglioma
In comparison with the previous edition of the classi-
fication of these tumours, the term jugulo-tympanic para-
ganglioma was changed into middle ear paraganglioma [8].
The characteristics of paragangliomas 
In the past, paragangliomas were most frequently treated 
as sporadic, which involved about 90% of cases [9]. The re-
maining 10% were regarded as familial cases. Current studies 
show that up to 40% of cases of tumours originating from 
paraganglial tissues may have a hereditary character [10].
There are 14 various genes which have been identified 
where germinal mutations can predispose one to the deve-
lopment of pheochromocytomas and paragangliomas. The 
most frequently identified mutations concern the SDH gene 
(succinate dehydrogenase complex) and are connected with 
the familial complex of pheochromocytomas and paragan-
gliomas (PCC/PGL). In the head and neck area this concerns, 
in particular the D and C subunits (SDHD, SDHC). Gene VHL 
mutations are also frequent in von Hippel-Lindau syndro-
me, and also in the RET protooncogene (rearranged during 
transfection protooncogene) leading to the development of 
the MEN2 multiple endocrine neoplasia as well as in the NF1 
(neurofibromin 1) in the neurofibromatosis type 1 [6, 11].
Paragangliomas usually form isolated lesions, whilst 
multifocal paragangliomas occur less frequently [12]. Multi-
focal paragangliomas more often occur among familial ones 
than in sporadic paragangliomas, which has its justification 
in the Knudson hypothesis (in sporadic cases, there must 
be 2 independent mutations in suppressor genes, whilst 
in hereditary cases, one mutation is congenital and the 
other — acquired).
Paragangliomas may also be classified with regards to 
their secretory abilities, into secretory (> 90%) and non-
-secretory (< 5%). The process of secretion is possible due 
to the presence of main cells, which are the building com-
ponent of paraganglia. The main cells are the ones which 
are able to produce catecholamines. Not all secretory para-
gangliomas produce sufficient amounts of the substance to 
induce clinical symptoms, that is why some authors define 
secretory paragangliomas as only those which cause clinical 
symptoms [13].
Table I. The division of paragangliomas 
Paragangliomas of sympathetic system Paragangliomas of parasympathetic system
Chromium salts staining Pheochromocytomas Non-pheochromocytomas
Location Located along sympathetic trunk Located in the vicinity of the large vessels of head and neck 
Secretory abilities Secretory (noradrenaline, adrenaline) Non-secretory 
Examples Para-aortic body paragangliomas (ogan of 
Zukerkandl)
Carotid body paraganglioma, 
jugulo-tympanic paraganglioma, vagal nerve paraganglioma
Rare locations: paraganglioma of the orbit, oral cavity, larynx, 
naso-pharynx, parathyroids 
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From a clinical point of view, paragangliomas may be 
either benign or malignant tumours. Malignant paraganglio-
mas are regarded as only those which are diagnosed after 
distant metastases have been found in the places where 
chromogenic tissue does not exist physiologically e.g. to the 
lymph nodes, bones, lungs or liver [1]. In the current WHO 
classification, it is assumed that all paragangliomas have 
metastatic potential. The term malignant paraganglioma 
was thus replaced with metastasising paraganglioma or 
paraganglioma with metastases [8]. Thus the current no-
menclature refers to the term “metastasising paraganglio-
ma” instead of “malignant paraganglioma”. The prevalence of 
metastatic paragangliomas is described as ranging between 
10–17%. However, this risk strictly depends on the type 
of germinal mutation underlying the hereditary forms. A 
mutation in subunit B of succinate dehydrogenase (SDHB) 
in a hereditary syndrome of pheochromocytomas and pa-
ragangliomas may lead to the development of metastases 
even in 40% of cases [6].
It must be stressed that 25% of paragangliomas located 
in the orbit and larynx are malignant. Also, about 15% of va-
gal paragangliomas and 5% of carotid and jugulotympanic 
have malignant potential.
Histopathologically, paragangliomas are built out of 2 
cell types: 
 — main cells with excessive eosinophilic cytoplasm and 
atypical cellular nuclei;
 — sustentacular cells of a spindle shape, located on the 
circumference of the main cell nests.
Tumour cell nests are surrounded with a rich vasculature. 
The lack of polarisation of the cells on the nest circumferen-
ces is a morphological property which allows for the diffe-
rentiation between paragangliomas and neuroendocrine 
tumours as this polarisation occurs in the latter The main 
cells are characterised with the expression of synaptophy-
sin, chromogranin A, CD56 and somatostatin receptors 2A, 
whilst they do not reveal the expression of cytokeratins, 
carcino-embryonic antigen (CEA) and calcitonin. Sustenta-
cular cells may be visualised after the application of S-100 or 
GFAP. No expression is found in these cells, neither there are 
epithelial or neuroendocrine markers present in them [8]. 
There are no well-defined and recognised histopathological 
criteria on the basis of which a metastatic (formerly — ma-
lignant) type of paraganglioma can be diagnosed. In some 
isolated reports, in which in the postoperative histopatho-
logical assessment of the necrosis, peri-neural infiltrations, 
capsular infiltration, increased mitotic activity and atypical 
mitotic figures, the patients were qualified for postoperative 
RTH, as the above properties have been regarded as the 
malignancy criteria [9].
In 2005 Kimura et al., published the scale of the eva-
luation of pheochromocytomas and extra-adrenal para-
sympathetic paragangliomas on the basis of the criteria 
of histological texture, cellularity, coagulative necrosis, 
vascular invasion and tumour capsule, proliferative index 
Ki-67 and the types of catecholamines secretion [14]. The 
application of the above scale allows to classify paragan-
gliomas to one of the three groups: well, moderately or 
poorly differentiated tumours. The differences between the 
groups correlate with the metastatic potential and survival 
rates. Yet, there is a group of well differentiated tumours 
which still produce metastases, which is indicative of the 
limitations of the practical application of the Kimura scale 
[15]. The histopathology of paragangliomas and metastatic 
tumours is usually the same. Only some metastatic tumours 
are characterised with a higher proliferative index or lower 
number of sustentacular cells [15]. The collective analysis 
of the patients with the diagnosis of paraganglioma or 
pheochromocytoma, 10-year probability or malignancy is 
estimated to be about 20% [16].
Symptoms
Clinical symptoms presented in the patients with dia-
gnosed paraganglioma are closely connected with the tu-
mour location. The most frequent symptoms are comprised 
of pulsation in the ears or tinnitus, hearing defects or loss, 
ear exudate, headaches or cranial nerve dysfunction, com-
prising: glossopharyngeal nerve (IX), vagal (X), auxiliary (XI), 
sublingual (XII), in particular in patients with a large tumour 
mass. Larger tumours in the area of the carotid body are 
visible in a laryngological assessment in the mid-pharynx 
or are palpable in the neck, which is the first symptom of 
paraganglioma, leading to the referral to a specialist and 
the commencement of a diagnostic proves. Sometimes 
hoarseness (resulting from the palsy of recurrent laryngeal 
nerve — branch X) and dysphagia are present.
The main symptom of the jugulotympanic paraganglio-
ma is pulsating tinnitus and conductive hearing defects. In 
the otoscopic assessment, it is often possible to find a blu-
eish tumour mass shining through the tympanic membrane. 
Once positive pressure is applied to the tympanic membra-
ne, during the examination with a pneumatic speculum, 
this mass may go pale. This phenomenon is named Brown’s 
symptom and is indicative of the vascular character of the 
tumour. Sometimes, paragangliomas are accompanied with 
atypical clinical symptoms such as excessive sweating (dia-
phoresis), facial redness, anxiety, vertigo, irregular heart beat 
and arterial hypertension. These symptoms are the effect 
of catecholamines secretion, and, in extreme cases may 
be life threatening. In some isolated cases, the loss of body 
weight and bone pain may suggest the malignant character 
of paraganglioma [17].
Imaging diagnostics 
On account of its accessibility, the classical and Doppler 
ultrasound examinations are used mainly for the lesions 
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located in the area of the carotid body — non-homogeno-
us, solid tumours with rich vasculature require extensive 
diagnostics. The examination which usually suggests a dia-
gnosis of paraganglioma as the first one is the contrast CT.
On account of the rich vascularisation of paraganglio-
mas, the typical CT image is a well delineated hyperdense 
tumour. CT also allows the visualisation of bone destruction, 
whose confirmation or exclusion allows to determine the 
advancement stage of paraganglioma (see Appendix). In 
the case of a suspected paraganglioma on contrast en-
hanced CT, MRI must be performed in order to verify it. 
Upon the administration of a gadolinium contrast agent, 
paragangliomas reveal strong enhancement. Moreover, the 
characteristic image of “salt and pepper” in T2-weigthed 
images allows confirmation of the character of a tumour, 
which in CT raised a suspicion of paraganglioma [18, 19]. 
That is why, first of all because of the large risk of a tumour 
haemorrhage, biopsy is not required in order to confirm 
diagnosis. The examination necessary for the qualification of 
patients for paraganglioma resection is angiography which 
allows visualisation of the network of vessels supplying 
blood and efferent vessels. The term, “the lyra symptom” 
encountered in publications, refers to the characteristic 
image of paraganglioma in angiography, when internal 
and external carotid arteries are pushed away from each 
other by the tumour mass developing between them. In 
the diagnostics of paragangliomas, some other imaging 
methods, belonging to the domain of nuclear medicine are 
used as well, comprising: positron emission tomography 
(68Ga-DOTATATE, 18F-FDG, 18F-DOPA tracers) and MIBG 131-I 
scintigraphy (iodine-labelled metaiodobenzylguanidine), 
also with the use of the labelled somatostatin analogues. An 
indication to perform such examinations is the diagnosis of 
multi-focal paragangliomas and familial paragangliomas (in 
particular with the presence of the SDH mutation) in order 
to exclude distant metastases [16].
Laboratory diagnostics with the suspicion of 
secretory paragangliomas 
In all patients in whose cases paragangliomas were dia-
gnosed on the basis of imaging diagnostics, it is necessary 
to perform biochemical diagnostic work comprising the 
determination of the excretion of fractionated methoxy-
-catecholamines (metanephrine, normetanephrine, me-
thoxytyramine) in 24-hour urine sampling or free methoxy-
-catecholamines in serum, depending on the possibilities 
of the centre in charge; chromogranin A level should be 
assessed as well [6]. The catecholamines metabolism and 
metabolites are presented in Figure 1. 
Treatment 
The treatment of paragangliomas is a multidisciplinary 
task. The choice of therapeutic procedures depends on 
the tumour location and measurements, the patient age, 
comorbidities, secretory function and the patient’s decision. 
The most appropriate final criterion, used for the analyses 
comparing the effectiveness of specific methods is local con-
trol (LC) and preservation of the nerve function. The overall 
survival (OS) is here of minor importance with respect to the 
benign character of the majority of lesions [1].
The following methods of treatment are used: 
 — active observation;
 — surgical resection;
 — embolization;
 — radiotherapy;
 — systemic treatment;
 — pharmacotherapy.










HVA — homovanillic acid 
VMA — vanillylmandelic acid
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Active observation 
This method of treatment is recommended especially 
in elderly patients with an asymptomatic disease, with si-
gnificant comorbidities. The justification for an active obse-
rvation is the slow tumour growth (0.5–5 mm annually) and 
the time of tumour doubling time of between 6 months to 
21 years [20, 21].
Surgical resection 
Surgery is possible in the majority of paraganglioma 
locations (especially in the case of cervical paragangliomas 
with a size below 5 cm). Tumour resection is the treatment 
of choice in patients with metastatic paragangliomas (tumo-
rectomy with cervical lymphadenectomy) or with secretory 
paragangliomas (in the comparison of the tumour resection 
with RTH alone, tumour stabilisation was achieved after irra-
diation with some minor effect regarding the inhibition of 
secretion). Rich vascularisation and head and neck location 
areas burden such surgery with a risk of neural and vascular 
damage as well as with the loss of baroreceptors reflex; this 
is especially true with bilateral resection of cervical paragan-
gliomas, which is connected with the deregulation of arterial 
blood pressure. In the case of vagal paragangliomas, the 
reported rate of nerve X damage is almost 100% [7]. The risk 
of death in patients with cervical and vagal paragangliomas 
undergoing surgery is 1.6% [22].
The contraindications for surgical resection comprise: 
 — skull base tumours (difficulties in obtaining complete 
tumour resection)
 — bilateral head and neck paragangliomas 
 — multifocal paragangliomas 
 — tumours > 5 cm (require the reconstruction of cervical 
vasculature)
Embolisation 
The administration of a vasoconstrictor is rarely used 
as an independent treatment method. The most frequently 
used embolization is done in combination with tumour re-
section which should be at best performed within 48 hours 
of the application of the embolising agent (polyvinyl alcohol, 
tris-acryl gelatine microspheres, ethanol, platinum spirals) 
in order to avoid inducing collateral circulation [23]. Embo-
lisation was for the first time described and recommended 
by Robertson in 1972. The time span between embolisation 
and the decision concerning consecutive treatment, inclu-
ding surgical intervention, depends on the resolution or 
decrease of the symptoms existing before embolisation; it is 
also necessary to perform follow-up examinations, including 
an angio-CT [24]. The advantages of this course of treatment 
comprise the decrease of the tumour mass, which improves 
resectability conditions and also the decrease of the vascular 
flow or even a complete occlusion of the vessels, leading to 
the reduction of the risk of bleeding during the procedure. 
It must be remembered, however, that in the case of the 
displacement of the occlusion material, the risk of ischaemic 
brain stroke increases.
Radiotherapy 
Irradiation is a generally recognised method of treating 
paragangliomas, the result of which is the loss of their cell 
division capability, the creation of vascular emboli and a 
consecutive vascular fibrosis. Currently, radiotherapy is re-
garded as the best method of paraganglioma treatment, ir-
respective of the evaluation of the tumour resectability. The 
objective of this type of treatment is not complete tumour 
regression, but the inhibition of its growth. The efficiency of 
RTH evaluated in follow-up imaging examinations is defined 
as the lack of tumour progression or its partial regression 
(partial regression in 61% patients — a reduction of the 
baseline tumour dimension by 23% on average). In com-
parison with surgery, radiotherapy allows the preservation 
of the neural function and is connected with a significantly 
lower risk of vascular complications. It is the method of cho-
ice in patients with a diagnosed skull base paraganglioma 
and vagal nerve paraganglioma. The applied radiotherapy 
methods are comprised of the standard 3D external beam 
radiotherapy (EBRT), stereotactic radiotherapy (SBRT) and 
radiosurgery (SRS). The conventionally fractionated EBRT 
is usually applied irrespective of the tumour size, up to 
a total dose of 45 Gy for 5 weeks [25]. There are reports 
suggesting that the recurrence rate increases above 1% 
when the total irradiation dose is below 40 Gy [26]. The 
techniques of stereotactic radiotherapy administered in a 
few fractions (usually 3–5) up to a total dose of 21–25 Gy or 
radiosurgery (12–32 Gy administered in a single dose) are 
applied in particular in the case of tumours which are not 
larger than 3 cm. Fractionating depends also on the tumour 
volume. There is also evidence of a higher risk of neuropathy 
after stereotactic treatment in comparison with EBRT. Better 
results were observed after a single dose of 15 Gy in com-
parison with a single dose of 13 Gy. It was proven that the 
radiotherapy results are independent of the radiotherapy 
technique which has been applied (EBRT vs SBRT vs SRS). 
However, an important aspect is the qualification criterion 
for each of these methods, which is the tumour size [1]. It 
was also proven that surgery performed after RTH does not 
improve the treatment results [27]. In secretory paragan-
gliomas, in spite of increasing EBRT doses to 64–70 Gy, no 
satisfactory effect inhibiting secretion is achieved; as a result, 
in such cases the method of choice is tumour resection with 
a potential postoperative RTH after the consideration of the 
histopathology results. American researchers performed a 
metanalysis of paraganglioma treatment methods, com-
prising: complete resection, partial resection, radiosurgery 
and partial resection in combination with radiosurgery. 
The best results with respect to disease recurrence were 
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obtained with the application of radiosurgery as an inde-
pendent method [28]. The generally accessible data from 
many publications point to a 5-year and 10-year local disease 
control after the application of radiotherapy in 99% and 
96% of patients respectively which shows that irradiation 
results are at least comparable or better than surgery [29]. 
On the basis of the American register, National Cancer Data, 
5-year survival totals 60% in the cases of paragangliomas 
metastasising to regional lymph nodes [7]. Radiotherapy is 
also connected with some adverse effects such as mucositis, 
xerostomia, nausea, progressive hearing loss leading to 
deafness, osteonecrosis, soft tissues fibrosis, brain necro-
sis, chronic otitis, otorrhea, nerve VI, VII, VIII palsy — after 
the administration of doses > 64 Gy, trismus (lockjaw), and 
also secondary cancers (sarcomas) [21, 30–32]. Mortality 
connected with conventional radiotherapy is estimated 
to be about 2%. No deaths related with radiosurgery have 
been reported [22]. According to Cummings, the treatment 
results after radiotherapy, depending on the symptoms, 
were as follows: in 79% patients tinnitus was reduced, 30% 
of patients reported hearing improvement and 5% com-
plete hearing recovery. 62% of patients do not experience 
neither improvement nor deterioration in hearing [33]. The 
improvement of the function of remaining cranial nerves 
concerns about 30% patients [1].
Systemic treatment
In the cases of diagnosing malignant paragangliomas, 
which, as was mentioned here, concern patients with me-
tastases, systemic treatment is the basic therapeutic option. 
The treatment should be conducted by experienced teams 
consisting of specialists in endocrinology, nuclear medicine 
and clinical oncology. For the treatment, radionuclides are 
applied, such as 131I-MIBG (in the case of adequate uptake 
confirmed in scintigraphy: 123I- or 131I-MIBG), and also isotope-
-labelled somatostatin analogues (in the cases of confirming 
the presence of somatostatin receptors: 99mTc Tectrotid or 
PET68Ga-Dotatate). Fast progression of the lesion may be an 
indication for the use of chemotherapy based on the CVD 
regimen (cyclophosphamide, vincristine, dacarbazine). Also 
etoposide, cisplatin and cytosine arabinoses are applied. The-
re are also isolated reports about the efficiency of temozolo-
mide. There are clinical trials in which the targeted treatment 
with the use of axitinib, pazopanib or sunitinib is studied [16].
Pharmacotherapy 
Pharmacological therapy has not used in a causative 
treatment although it is frequently applied in the cases 
of secretory paragangliomas especially before a planned 
surgery. The medication of first choice comprises selective 
alpha-1-blockers as these drugs control arterial pressure 
and prevent catecholaminergic crisis and tachycardia during 
surgery. In the case of a lack of satisfactory haemodynamic 
control, it is also possible to include calcium channel bloc-
kers into the therapy. Beta-blockers may be used in order 
to control tachycardia as late as 2–3 days after the use of an 
alpha-1-blocker. If the drugs inhibiting the beta receptors 
are introduced sooner there is a risk of developing hyper-
tensive shock [6, 34].
Conclusions
Paragangliomas, in spite of their very rare incidence, with 
respect to their biological properties, present themselves as 
a heterogenous group of cancers. The symptoms of disease 
are strictly connected with the location of the tumour and 
the characteristic image observed in CT and MRI is sufficient 
to make a diagnosis without the necessity of a cytological 
or histopathological assessment. The therapeutic pattern 
provides some options for choice between observation and 
on-going check-ups, surgery and conservative treatment. 
The most significant criteria determining the treatment 
method are tumour location, size and hormonal activity. 
Comparable results after tumour resection and radiotherapy 
conclude that the choice of treatment is determined by the 
number of possible complications after the application of 
each of the methods. Subsequently, radiotherapy may be 
regarded as the treatment of choice in the treatment of head 
and neck paragangliomas.
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Table III. Shamblin’s modified classification of paragangliomas [40, 41]
Stage Tumour size Cervical vessel involvement or infiltration in the tumour 
area 
Difficulty degree of tumour resectability
I < 4 cm The tumour does not involve or infiltrate cervical vessels No difficulties 
II > 4 cm Partially involves cervical vessels Difficult 
IIIA > 4 cm Closely involves cervical vessels Difficult, requires vessel correction, removal, or 
replacement 
IIIB Each Stage I, II or III in Shamblin’s original classification with 
the infiltration of cervical vessels 
The clinical and/or histopathological confirmation of 
the vascular wall invasion is necessary 
Table II. Shamblin’s classification of paragangliomas [39]
Stage Tumour Difficulty degree of 
tumour resectability 
Surgery 
I The tumour separates ICA and ECA, attaches to the bifurcation Low Routine dissection 
II Partly covers the vessels Medium Subintimal dissection 
III Closely covers the vessels High Partial or complete vascular resection 
Glasscock-Jackson Classification 
Cervical body paragangliomas [35]
• I — small tumour covering the area of the jugular vein 
bulb, middle ear and mastoid process
• II — tumour growing below internal acoustic meatus – 
intracranial expansion possible 
• III — tumour expanding to the top of the petrous py-
ramid of the temporal bone — intracranial expansion 
is possible 
• IV — the tumour expanding beyond the top of the 
petrous pyramid of the temporal bone to the clivus or 
subtemporal fossa — intracranial expansion is possible
Tympanic paragangliomas [36]
• Period I — small tumour in the area of promontorium
• Period II — the tumour fills the tympanic cavity 
• Period III — the tumour fills the tympanic cavity, pene-
trating into the mastoid process 
• Period IV — the tumour fills the tympanic cavity, mastoid 
process, external acoustic meatus and may infiltrate 
towards internal carotid artery 
Appendix
Fisch and Mattox classification [37, 38]
The classification of jugulo-tympanic paragangliomas (for-
mer nomenclature)
• stage A — tumour develops from tympanic plexus 
• stage B — tumour develops is hypotympanum, infiltra-
tes middle ear and mastoid process 
• stage C1 — tumour destroys the foramen of the carotid 
artery without infiltrating carotid artery 
• stage C2 — tumour destroys the vertical part of the 
carotid artery canal
• stage C3 — tumour destroys the horizontal part of the 
carotid artery canal, without infiltrating foramen lace-
rum 
• stage C4 — tumour infiltrates foramen lacerum and 
cavernous sinus 
• stage De1/2 — tumour proliferates intracranially, but 
epidurally: De1 not more than 2 cm, De2 — more than 
2 cm; 
• stage Di1/2/3 — tumour proliferates intracranially and 
in intradural manner: Di1 do 2 cm; Di2 — between 2 and 
4 cm; Di3 — more than 4 cm.
